Drug Profile
Itolizumab - Biocon/Equillium
Alternative Names: Alzumab-L; Anti-CD6 monoclonal antibody - Biocon/CIMAB; Anti-CD6 monoclonal antibody h-T1; Anti-CD6-monoclonal-antibody-Biocon; Bmab600; EQ-001; h T1; Humanised anti-CD6 monoclonal antibody ior t1; T12 antibody; T12 monoclonal antibody; T1h; T1hTLatest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Center of Molecular Immunology
- Developer Biocon; Biotech Pharmaceutical; Equillium
- Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Urologics
- Mechanism of Action CD6 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Plaque psoriasis
- Registered Cytokine release syndrome; SARS-CoV-2 acute respiratory disease
- Phase III Graft-versus-host disease
- Phase II Ulcerative colitis
- Phase I Lupus nephritis; Systemic lupus erythematosus
- No development reported Asthma; Autoimmune disorders; Multiple sclerosis; Psoriasis
- Discontinued Rheumatoid arthritis
Most Recent Events
- 25 Mar 2024 Equillium anticipates results of the interim review by the data monitoring committee of phase III EQUATOR trial in Acute graft-versus-host disease in the third quarter of 2024
- 18 Jan 2024 Equillium completes a phase Ib trial in Systemic lupus erythematosus and Lupus nephritis in Poand, India and USA (SC, injection) (NCT04128579)
- 13 Nov 2023 Efficacy data from a phase Ib EQUALISE trial in Multiple sclerosis presented at the annual meeting of the American College of Rheumatology (ACR-2023)